contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nanologica-announces-outcome-of-directed-share-issues

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Nanologica is a life science tools company that develops, manufactures and sells advanced input products to pharmaceutical companies. Nanologica's silica-based products are specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Nanologica operates in a global niche market for drugs for the treatment of diabetes and obesity. Nanologica was founded in 2004 and is headquartered in Södertälje.

Nanologica

Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the...

<div class="mfn-preamble"><p><strong>Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and allotted in accordance with the resolutions.</strong></p></div><div class="mfn-body"><p>Ardena Sweden AB has subscribed for and been allotted all 21,453,780 shares in the set-off issue. The subscription price was SEK 0.40 per share, corresponding to a total subscription amount of approximately SEK 8.6 million, which was settled by set-off.</p><p>The directed issue of 12,750,000 shares has been fully subscribed and allotted to a limited group of investors at a subscription price of SEK 0.40 per share, which means that the Company will receive issue proceeds of approximately SEK 5.1 million before deductions of costs attributable to the issue. For further information on the directed new issues, please refer to the separate press release dated 30 January 2026.</p></div><div class="mfn-footer mfn-contacts mfn-31afac252a6d"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Johanna Johansson<br>Director IR, Communications and Marketing<br>johanna.johansson@nanologica.com<br>+46 72 211 21 90</p></div><div class="mfn-footer mfn-about mfn-c09c1d849689"><p><strong class="mfn-heading-1">About Nanologica AB (publ)</strong><br>Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit <a href="http://www.nanologica.com" rel="noopener">www.nanologica.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a class="mfn-generated mfn-primary" href="https://storage.mfn.se/0a6ad742-c42f-4e32-b66e-4b6d107e8ec6/nanologica-announces-outcome-of-directed-share-issues.pdf" rel="noopener">Nanologica Announces Outcome of Directed Share Issues</a></p></div>

Nanologica Announces Outcome of Directed Share Issues

Neste

Finnair

Kemira

Orthex

Nokian Tyres

Kesko

Tokmanni Group

Puuilo

Öljyn hinnan vaikutus Helsingin pörssiin: historia, vaikutusmekanismit ja riskit